straIL/apo2l ELISA Kit

Storage Instruction:Store the kit at 4°C.
Description:
Tumor necrosis factor-related apoptosis inducing ligand (TRAIL)/Apo2L is a type II transmembrane protein that was
identified and cloned based on its sequence homology with members of the TNF ligand family. Both the transmembrane
and soluble recombinant forms of TRAIL can rapidly induce apoptosis in a wide variety of transformed human cell lines in
vitro, yet no cytotoxicity is observed with normal human cell lines, even though TRAIL and its receptors are expressed in
both cell types. TRAIL is expressed constitutively in many tissues such as liver, lung, placenta, kidney, spleen, peripheral
lymphocyte, etc. It is highly expressed in cancer cells and selectively kills the cancer cells by binding two cell-surface
receptors, DR4 and DR5, which are highly expressed in cancer cells. TRAIL induces cancer apoptosis independently of
p53 gene mutation. Two additional TRAIL decoy receptors (DcR1 and DcR2) do not trigger an apoptotic signal in normal
cells and have been proposed to confer protection from TRAIL-inducing apoptosis. TRAIL may also play roles in immune
responses, autoimmune disorders and HIV infections. TRAIL can interact with five different members of the TNF receptor
superfamily, two of which contain a death domain, and can mediate an apoptotic response. TRAIL may also be a marker
for progression of cancer.